{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:15:25Z","timestamp":1791324925037,"version":"4.3.1"},"reference-count":39,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T00:00:00Z","timestamp":1417564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Meda Pharma GmbH & Co. KG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The new target for the treatment of actinic keratosis (AK) is the detection and clearance of clinical and subclinical lesions across an entire sun\u2010exposed field. This is because patients with AK have field cancerization as ultraviolet light affects the entire sun\u2010exposed area and because it is not possible to predict which AK lesions will progress into invasive squamous cell carcinoma. To fully assess the effectiveness of field\u2010directed therapies against the full burden of AK, a new efficacy concept has been developed which is based on the reduction in lesions from Lmax, or the maximum lesion count during treatment. This new parameter enables the efficacy of a field\u2010directed therapy against both clinical and subclinical lesions to be assessed. Imiquimod 3.75% is a novel field\u2010directed therapy which uniquely can detect and clear both clinical and subclinical lesions across a large sun\u2010exposed field such as the full face or balding scalp, and so far is the only AK treatment to have had its efficacy assessed with the Lmax concept. The detection of subclinical lesions is evidenced by an increase in lesion count during each of the 2\u2010week treatment cycles, which are separated by a 2\u2010week treatment\u2010free interval. The median percentage reduction in lesions from Lmax with imiquimod 3.75% is 92%, and the effective clearance of both clinical and subclinical lesions leads to sustained lesion clearance for at least 1\u00a0year. Imiquimod 3.75% has an acceptable tolerability profile. Rest periods from treatment may be taken if required to manage local skin reactions, with no loss in efficacy. In conclusion, Lmax and imiquimod 3.75% together set the new standard in the management of patients with AK.<\/jats:p>","DOI":"10.1111\/jdv.12824","type":"journal-article","created":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T11:43:06Z","timestamp":1417606986000},"page":"9-14","source":"Crossref","is-referenced-by-count":15,"title":["Lmax and imiquimod 3.75%: the new standard in AK management"],"prefix":"10.1111","volume":"29","author":[{"given":"E.","family":"Stockfleth","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Dermatologie Venerologie und Allergologie St. Josef\u2010Hospital Ruhr\u2010Universit\u00e4t Bochum Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,3]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1462","article-title":"The paradigm shift in treating actinic keratosis: a comprehensive strategy","volume":"11","author":"Stockfleth E","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_3_1","first-page":"1","article-title":"Tyring SK. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel","volume":"55","author":"Berman B","year":"2006","journal-title":"J Fam Pract"},{"key":"e_1_2_6_4_1","first-page":"43","article-title":"Actinic keratoses: a comprehensive update","volume":"2","author":"Ibrahim SF","year":"2009","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"e_1_2_6_5_1","first-page":"s45","article-title":"Actinic keratoses: past, present and future","volume":"9","author":"Fenske NA","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12246.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02560.x"},{"issue":"1","key":"e_1_2_6_8_1","first-page":"3","article-title":"Actinic keratosis and field cancerisation","volume":"21","author":"Stockfleth E","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000254893"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.01047.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910460303"},{"key":"e_1_2_6_12_1","first-page":"201","article-title":"Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications","volume":"87","author":"Feldman SR","year":"2011","journal-title":"Cutis"},{"key":"e_1_2_6_13_1","first-page":"651","article-title":"Development of a treatment algorithm for actinic keratoses: a European Consensus","volume":"18","author":"Stockfleth E","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/ejd.2014.2265","article-title":"Reduction in lesions from Lmax: a new concept for assessing efficacy of field\u2010directed therapy for actinic keratosis. Results with imiquimod 3.75%","volume":"24","author":"Stockfleth E","year":"2014","journal-title":"Eur\u00a0J Dermatol"},{"key":"e_1_2_6_15_1","first-page":"227","article-title":"Zyclara (imiquimod) cream, 3.75%","volume":"8","author":"Gupta AK","year":"2010","journal-title":"Skinmed"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.549128"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.004"},{"key":"e_1_2_6_18_1","first-page":"166","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double\u2010blind, placebo\u2010controlled studies","volume":"13","author":"Swanson N","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111170"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07942.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.047"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04561.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01324.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"key":"e_1_2_6_25_1","first-page":"30","article-title":"The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation","volume":"70","author":"Gupta AK","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119649"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.41"},{"key":"e_1_2_6_28_1","first-page":"36","article-title":"Mechanism of action and other potential roles of an immune response modifier","volume":"79","author":"Gaspari AA","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107808"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1109"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2006.00414.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg016"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-7"},{"key":"e_1_2_6_34_1","unstructured":"StockflethE.Long\u2010term sustained lesion clearance from Lmax with imiquimod 3.75% a new field\u2010directed treatment for actinic keratosis. Poster presented at EADV 2013 Abstract P0384."},{"key":"e_1_2_6_35_1","first-page":"165","article-title":"Complete clearance is sustained for at least 12\u00a0months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream","volume":"10","author":"Hanke CW","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_36_1","unstructured":"GuptaG.Imiquimod 3.75% and risk of progression to squamous cell carcinoma from actinic keratosis: case studies of potential benefit. Poster presented at EADV 2012 Abstract P0504."},{"key":"e_1_2_6_37_1","unstructured":"GuptaG.Effective clearance of actinic keratosis with imiquimod 3.75%: case study confirming the need for repeat immune stimulation with two treatment cycles. Poster presented at EADV 2012 Abstract P0503."},{"key":"e_1_2_6_38_1","first-page":"22","article-title":"Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients","volume":"1","author":"Werschler WP","year":"2008","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008786004974"},{"key":"e_1_2_6_40_1","unstructured":"AlomarA.Efficacy of imiquimod 3.75% from Lmax in patients with and without rest periods during treatment. Poster presented at EADV 2013 Abstract P0536."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12824","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T17:45:45Z","timestamp":1694454345000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,3]]},"references-count":39,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/jdv.12824"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12824","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,3]]}}}